177 related articles for article (PubMed ID: 20558841)
1. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
2. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
Cagnetta A; Caffa I; Acharya C; Soncini D; Acharya P; Adamia S; Pierri I; Bergamaschi M; Garuti A; Fraternali G; Mastracci L; Provenzani A; Zucal C; Damonte G; Salis A; Montecucco F; Patrone F; Ballestrero A; Bruzzone S; Gobbi M; Nencioni A; Cea M
Clin Cancer Res; 2015 Sep; 21(17):3934-45. PubMed ID: 25964294
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
5. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Olesen UH; Thougaard AV; Jensen PB; Sehested M
Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
7. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Nakamura N; Hara T; Shimizu M; Mabuchi R; Nagano J; Ohno T; Kochi T; Kubota M; Shirakami Y; Goto N; Ito H; Saito K; Tanaka T; Moriwaki H; Tsurumi H
Int J Hematol; 2015 Sep; 102(3):327-34. PubMed ID: 26243621
[TBL] [Abstract][Full Text] [Related]
8. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP
Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
11. NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
Zerp SF; Vens C; Floot B; Verheij M; van Triest B
Radiother Oncol; 2014 Feb; 110(2):348-54. PubMed ID: 24412016
[TBL] [Abstract][Full Text] [Related]
12. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
[TBL] [Abstract][Full Text] [Related]
13. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model.
Lim JY; Lee SE; Park G; Choi EY; Min CK
Exp Hematol; 2014 Oct; 42(10):862-6.e3. PubMed ID: 24971697
[TBL] [Abstract][Full Text] [Related]
17. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
18. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
19. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
20. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]